The quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) administered with routine pediatric vaccines is safe and immunogenic regardless of the schedule and does not affect the immunogenicity or safety of the concomitant vaccine, according to a study published in Vaccine. Anthony D. Johnson, MD, and colleagues evaluated, in infants/toddlers, five schedules of the MenACYW-TT conjugate vaccine: 2, 4, 6, and 12 months; 2, 4, 6, and 15 months; 2, 4, and 12 months; 6 and 12 months; and 12 months alone. Routine pediatric vaccines (DTaP-IPV/ Hib, PCV7/PCV13, MMR, and varicella) were administered per approved schedules. Tenderness and irritability were the most frequent injection site and systemic reactions. Similar proportions of participants achieved an hSBA titer of at least 1:8 for all four serogroups regardless of whether two or three doses were administered in the first year of life. Following a second-year dose, 91%-100% of participants achieved the threshold for all four serogroups in all schedules regardless of the number of doses in the first year of life.
